Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
CSCC
HNSCC
OSCC
anti-PD 1
checkpoint inhibition
immunotherapy
neoadjuvant
salvage surgery
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
06
2022
accepted:
10
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Prognosis of patients with recurrent or metastatic head and neck cancer is generally poor. Adjuvant immunotherapy (IT) featuring immune checkpoint inhibition (ICI) is standard of care in advanced stage head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (CSCC). ICI response rates in CSCC are described as higher than in HNSCC. IT is constantly shifting into earlier disease stages which confronts the surgeon with immunotherapeutically pre-treated patients. It is therefore becoming increasingly difficult to assess which patients with symptomatic tumor disease and a lack of curative surgical option might benefit from salvage surgery. The following 6 cases describe therapeutic decision-making regarding ICI and (salvage) surgery in patients with advanced stage HNSCC or CSCC. ICI is rapidly expanding its frontiers into the neoadjuvant setting, frequently confronting the surgeon with heavily pretreated patients. Salvage surgery is a viable therapeutic concept despite the rise of systemic treatment options. Decision-making on surgical intervention in case of a salvage surgery remains an individual choice. For neoadjuvant ICI monitoring regarding pathological tumor response or tumor necrosis rate, we suggest correlation between the initial biopsy and the definite tumor resectate in order to increase its significance as a surrogate marker. Scheduling of neoadjuvant ICI should be further investigated, as recent studies indicate better outcomes with shorter time frames.
Sections du résumé
Background
Prognosis of patients with recurrent or metastatic head and neck cancer is generally poor. Adjuvant immunotherapy (IT) featuring immune checkpoint inhibition (ICI) is standard of care in advanced stage head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (CSCC). ICI response rates in CSCC are described as higher than in HNSCC. IT is constantly shifting into earlier disease stages which confronts the surgeon with immunotherapeutically pre-treated patients. It is therefore becoming increasingly difficult to assess which patients with symptomatic tumor disease and a lack of curative surgical option might benefit from salvage surgery.
Case presentations
The following 6 cases describe therapeutic decision-making regarding ICI and (salvage) surgery in patients with advanced stage HNSCC or CSCC.
Conclusions
ICI is rapidly expanding its frontiers into the neoadjuvant setting, frequently confronting the surgeon with heavily pretreated patients. Salvage surgery is a viable therapeutic concept despite the rise of systemic treatment options. Decision-making on surgical intervention in case of a salvage surgery remains an individual choice. For neoadjuvant ICI monitoring regarding pathological tumor response or tumor necrosis rate, we suggest correlation between the initial biopsy and the definite tumor resectate in order to increase its significance as a surrogate marker. Scheduling of neoadjuvant ICI should be further investigated, as recent studies indicate better outcomes with shorter time frames.
Identifiants
pubmed: 36389668
doi: 10.3389/fimmu.2022.970823
pmc: PMC9646561
doi:
Types de publication
Review
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
970823Informations de copyright
Copyright © 2022 Olmos, Lutz, Büntemeyer, Glajzer, Nobis, Ries, Möst, Eckstein, Hecht, Gostian, Erdmann, Foerster, Kesting and Weber.
Déclaration de conflit d'intérêts
MW has consulting contracts with the pharmaceutical companies Sanofi and Bristol Myers Squibb. MiE participated in an advisory board by Bristol Myers Squibb. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2021 Jul 22;12:670391
pubmed: 34367136
Front Oncol. 2021 Sep 06;11:727433
pubmed: 34552878
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
J Immunother Cancer. 2021 May;9(5):
pubmed: 33963014
N Engl J Med. 2015 Aug 6;373(6):521-9
pubmed: 26027881
Radiat Oncol. 2016 Jan 20;11:6
pubmed: 26792072
Ann Transl Med. 2019 Jul;7(Suppl 3):S75
pubmed: 31576284
Nat Commun. 2022 Jul 25;13(1):4298
pubmed: 35879302
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Front Med (Lausanne). 2019 Mar 13;6:27
pubmed: 30931305
Trends Mol Med. 2019 Mar;25(3):185-197
pubmed: 30686761
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589
Oral Oncol. 2020 Mar;102:104580
pubmed: 31991265
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34599023
J Clin Oncol. 2019 Nov 10;37(32):3000-3008
pubmed: 31557067
Br J Dermatol. 2000 Sep;143(3):513-9
pubmed: 10971322
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
Nat Med. 2021 Feb;27(2):256-263
pubmed: 33558721
Nat Commun. 2021 Dec 22;12(1):7348
pubmed: 34937871
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:38-43
pubmed: 31833610
Eur J Cancer. 2020 Mar;128:60-82
pubmed: 32113941
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Oncoimmunology. 2019 Mar 1;8(5):e1581530
pubmed: 31069141
Eur J Nucl Med Mol Imaging. 2022 May;49(6):2010-2022
pubmed: 34957526
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Clin Cancer Res. 2022 Feb 1;28(3):468-478
pubmed: 34667025
Oral Oncol. 2016 Jan;52:75-84
pubmed: 26728105
J Am Acad Dermatol. 2018 Feb;78(2):237-247
pubmed: 29332704
Surg Oncol Clin N Am. 2015 Jul;24(3):491-508
pubmed: 25979396
J Clin Oncol. 2020 Sep 1;38(25):2916-2925
pubmed: 32673170
Bull Cancer. 2020 Jun;107(6):640-641
pubmed: 31610910
Virulence. 2015;6(3):244-8
pubmed: 25654476
Lancet Oncol. 2018 Feb;19(2):151-153
pubmed: 29361473
Clin Cancer Res. 2022 Apr 1;28(7):1345-1352
pubmed: 35338369
Oral Oncol. 2017 Apr;67:1-9
pubmed: 28351561
Front Oncol. 2020 Dec 02;10:566315
pubmed: 33344227
Curr Oncol. 2021 Nov 14;28(6):4686-4701
pubmed: 34898553
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Semin Radiat Oncol. 2020 Jul;30(3):212-217
pubmed: 32503785
Oncotarget. 2020 Jan 14;11(2):188-211
pubmed: 32010431
Nature. 2021 Sep;597(7875):279-284
pubmed: 34471285
Oral Oncol. 2019 Jul;94:8-13
pubmed: 31178216
Clin Cancer Res. 2021 Jan 1;27(1):357
pubmed: 33397681
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Eur J Cancer. 2018 Jun;96:25-33
pubmed: 29660597
Clin Cancer Res. 2021 Aug 15;27(16):4557-4565
pubmed: 34187851
Oncotarget. 2017 Feb 14;8(7):12145-12157
pubmed: 28076333
Eur J Dermatol. 2020 Aug 1;30(4):372-376
pubmed: 32969798
Front Oncol. 2020 Jun 18;10:801
pubmed: 32626653
JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):871-878
pubmed: 34473219
Hematol Oncol Clin North Am. 2021 Oct;35(5):1009-1020
pubmed: 34226077
Clin Transl Radiat Oncol. 2021 Mar 26;28:71-78
pubmed: 33889760
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152
pubmed: 32665297
Cancer. 2018 Nov 1;124(21):4163-4164
pubmed: 30289965
J Clin Oncol. 2014 Sep 1;32(25):2735-43
pubmed: 25049329
J Craniomaxillofac Surg. 2014 Oct;42(7):1087-94
pubmed: 24556525
Nat Med. 2021 Feb;27(2):301-309
pubmed: 33558722
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279
J Craniomaxillofac Surg. 2016 Aug;44(8):1061-6
pubmed: 27255408
Crit Rev Oncol Hematol. 2020 Jun;150:102966
pubmed: 32371338
Eur J Surg Oncol. 2020 Jun;46(6):1052-1058
pubmed: 32014275
JAMA Oncol. 2020 Oct 1;6(10):1563-1570
pubmed: 32852531
Oncologist. 2010;15(12):1320-8
pubmed: 21147868
Nat Commun. 2021 Nov 19;12(1):6770
pubmed: 34799585
Head Neck. 1993 Jan-Feb;15(1):16-9
pubmed: 8416850
Clin Exp Immunol. 2012 Sep;169(3):205-12
pubmed: 22861359
Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8
pubmed: 12117328
Oral Oncol. 2009 Apr-May;45(4-5):409-15
pubmed: 18715812
Curr Opin Oncol. 2020 May;32(3):178-186
pubmed: 32209823
Front Oncol. 2021 Jul 21;11:720951
pubmed: 34368002
BMC Cancer. 2014 Dec 17;14:969
pubmed: 25518732